EICHOR
● Not Yet Recruiting
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Condition: Intrahepatic Cholangiocarcinoma (Icc) · Sponsor: Zhejiang Cancer Hospital
About this study
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma. Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.
This description comes directly from the study's public registry record.
Talk to the study team
Gaojun Teng, MD · +86 13805171500 · gjteng@seu.edu.cn
Binyan Zhong, MD · +86 15850522044 · byzhongir@sina.com
Always discuss trial participation with your own doctor first.
Locations (18)
| The First Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | — |
| Jinshazhou Hospital of Guangzhou University of Chinese Medicine | Guangzhou, Guangdong, China | — |
| Guangdong Second People's Hospital | Guangzhou, Guangdong, China | — |
| The Affiliated Panyu Central Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | — |
| The Second Affiliated Hospital of Guangdong Medical University | Guangzhou, Guangdong, China | — |
| Jiangmen Central Hospital | Jiangmen, Guangdong, China | — |
| Wuhan Union Hospital of China | Wuhan, Hubei, China | — |
| The Second Xiangya Hospital of Central South University | Changsha, Hunan, China | — |
| The Third Xiangya Hospital of Central South University | Changsha, Hunan, China | — |
| Ganzhou Hospital-Nanfang Hospital, Southern Medical University | Ganzhou, Jiangxi, China | — |
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi, China | — |
| The Affiliated Hospital of QingDao University | Qingdao, Shandong, China | — |
+ 6 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07691515